Treatment failure patterns in early versus late introduction of CAR T-cell therapy in large B-cell lymphoma Magdalena Corona Andrew Ip Roni Shouval Research01 Feb 2025Bone Marrow Transplantation P: 1-8 Targeting fucosyltransferase FUT8 as a prospective therapeutic approach for DLBCL ...
Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma CD19-targeted CAR T cells have transformed the management of patients with relapsed and/or refractory large B cell lymphoma, and these therapies are increasingly being administered as earlier-line therapies. Nonethel...
As a result of the findings, the FDA approved the CD30-targeted antibody-drug conjugate in March 2018 for use in combination with chemotherapy as a frontline treatment for adult patients with stage III/IV classical Hodgkin lymphoma. Moreover, in mantle cell lymphoma (MCL), the promising activit...
Chemotherapy represents an essential pillar for the treatment of various forms of hematological malignancies. However, a common theme emerges where these chemotherapy agents are usually associated with nonspecific toxicities and increasing drug resistance, presumably because of their high potency but low tumo...
AstraZeneca’s Calquence Gains FDA Approval for First-Line Mantle Cell Lymphoma Treatment 4d ago The FlyDrugmakers to push Trump to pause price negotiations, Bloomberg reports 7d ago AZN BMY The FlyIonis unveils pipeline plan for 2025, expects 4 independent product launches 7d ago AZN IONS ...
(mAbs) such as rituximab and obinutuzumab designed to specifically bind an antigen on a cancerous cell have been proven to play an essential role in lymphoma treatment [1,2,3,4]. With the development of mAb technologies, antibody–drug conjugates (ADCs), comprising a mAb connected to a ...
STAT Plus: An entertaining biotech fight, and a ‘nail in the coffin’ for transplants in mantle cell lymphoma Health Angus Chen STAT Plus: With promising early data in triple negative breast cancer, a new bispecific heats up Health Angus Chen STAT Plus: Stem cell transplant not needed...
(NMPA) for two indications, including the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, and the treatment of adult patients with follicular lymphoma that...
Odronextamab is currently under regulatory review for the treatment of R/R FL and diffuse large B-cell lymphoma (DLBCL) by theU.S. Food and Drug Administration, with a target action date of March 31, 2024, as...
InnoCare Pharma, a leading biopharmaceutical company, announced the latest clinical data of its Bruton Tyrosine Kinase inhibitor orelabrutinib at the 17th International Conference on Malignant Lymphoma.